Are you having memory problems or trouble thinking clearly? Have you been diagnosed with Mild Cognitive Impairment (MCI) or dementia due to early Alzheimer’s disease (AD)? Are you interested in participating in a clinical trial to help better understand if a new medication may slow the progression of Alzheimer’s disease and evaluate a new potential treatment for individuals with early AD.
The Tauriel study is assessing the dose levels, safety, tolerability and effectiveness of a new investigational medication (MTAU9937A, a monoclonal antibody - passive vaccine - that may halt or reduce the spread of tau in the brain) to determine whether it can stop or slow the progression of symptoms of early AD. The sponsor of this study is Genentech pharmaceutical company.
You may be eligible for the Tauriel study if you are:
- Male or female
- Age 50 - 80
There is no cost associated with participating in this trial.